According to a Phase I study led by researchers at The University of Texas MD Anderson Cancer Center, published in Nature ...

Histotripsy is a non-invasive treatment, approved by the Food and Drug Administration (FDA) in 2023, that uses ultrasound energy to destroy liver tumors in a single outpatient procedure. This includes ...

Anderson inks partnership powered by AI cancer diagnostics to develop genomic tools that improve cancer diagnosis and treatment decisions.

At The University of Texas MD Anderson Cancer Center, our mission has always been clear: to end cancer. Achieving this goal requires more than just groundbreaking research and exceptional patient care ...

Naval Daver, MD, who leads a number of acute myeloid leukemia (AML) research trials at MD Anderson Cancer Center in Houston, looks forward to a future where the treatment for AML is truly personalized ...

Ochsner Health is expanding its partnership with The University of Texas MD Anderson Cancer Center to Slidell Memorial Hospital, bringing one of the nation’s most advanced cancer treatment programs to ...

LIXTE Biotechnology Holdings (NASDAQ: LIXT) announced an expansion of its collaboration with The University of Texas ...

The University of Texas MD Anderson Cancer Center and SOPHiA GENETICS today announced a strategic collaboration that unites SOPHiA GENETICS' ...

Ever since early February, when former FDA Commissioner Robert Califf publicly bemoaned the progress of precision medicine, I wanted to find out whether other people felt similarly discouraged. I got ...